Product Description
A Novel T-cell Bispecific Antibody That Targets the Human Carcinoembryonic Antigen (CEA) on Tumor Cells and CD3 on T Cells (Sourced from: https://clinicaltrials.gov/ct2/show/NCT02324257)
Mechanisms of Action: CEA Binder,CD3 Binder
Novel Mechanism: Yes
Modality: Bispecific Antibody
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Hoffmann-La Roche
Company Location: BASEL SWITZERLAND V8
Company CEO: Severin Schwan
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, France, Israel, Korea, Spain, Taiwan, United Kingdom, United States
Active Clinical Trial Count: 1
Highest Development Phases
Phase 2: Non-Small-Cell Lung Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| Morpheus Lung | P2 |
Active, not recruiting |
Non-Small-Cell Lung Cancer |
2025-09-30 |
45% |
| Morpheus Lung | P2 |
Active, not recruiting |
Non-Small-Cell Lung Cancer |
2025-09-30 |
45% |
| Morpheus Lung | P2 |
Active, not recruiting |
Non-Small-Cell Lung Cancer |
2025-09-30 |
45% |
| Morpheus Lung | P2 |
Active, not recruiting |
Non-Small-Cell Lung Cancer |
2025-09-30 |
45% |